Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery

Core Insights - Rakovina Therapeutics Inc. is advancing innovative cancer therapies through AI-powered drug discovery and has recognized Dr. Artem Cherkasov for his contributions in this field [1][4] Company Overview - Rakovina Therapeutics is a biopharmaceutical research company focused on developing innovative cancer treatments using unique technologies for targeting DNA-damage response, powered by AI [5] - The company utilizes proprietary platforms such as Deep Docking™ and Enki™ to enhance the pace of drug candidate review and optimization [5] Key Collaborations - Dr. Artem Cherkasov, a professor at the University of British Columbia and principal investigator at the Vancouver Prostate Centre, serves as a key scientific advisor to Rakovina Therapeutics [2][3] - Rakovina holds exclusive access to the Deep Docking™ platform, which is instrumental in developing novel DNA-damage response inhibitors aimed at improving treatment outcomes for cancers with limited options [3] Technological Advancements - The Deep Docking™ platform is an AI engine capable of screening billions of molecules to identify promising drug candidates with speed and precision [2] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [6]